解决动物模型与人类阿尔茨海默氏症病理学之间的差异:对翻译研究的影响
Baruh Polis1, Abraham O Samson1
1Bar-Ilan University Azrieli Faculty of Medicine, Safed, Israel.
Journal of Alzheimer's disease : JAD
|March 22, 2024
概括
对阿尔茨海默病 (AD) 研究的转基因小鼠模型显示,复制人类AD病理学的局限性,导致临床试验失败. 改善临床前研究需要了解模型差异,并提高研究设计,以获得更好的治疗转化.
科学领域:
- 神经科学是一个神经科学.
- 生物医学研究生物医学研究
- 病理学 病理学 病理学
背景情况:
- 转基因动物模型,特别是小鼠,对于研究阿尔茨海默病 (AD) 的特征,如粉样质斑块和神经纤维状结,至关重要.
- 尽管这些模型有助于理解AD的病原体,但它们往往无法准确地代表人类的AD病理,从而导致翻译性挑战.
- 在动物模型中的有希望的临床前发现和阿尔茨海默氏症治疗药物的人类临床试验中的令人失望的结果之间存在很大的差距.
研究的目的:
- 分析动物模型与人类阿尔茨海默病 (AD) 病理学之间的差异.
- 在临床前AD研究中识别当前实验模型的局限性.
- 提出对AD病变的新视角,并建议对临床前研究设计进行改进.
主要方法:
- 现有阿尔茨海默病 (AD) 动物模型的文献综述和分析.
- 在动物模型中对神经病理学的比较分析与人类AD.
- 讨论导致AD药物开发中翻译失败的因素.
主要成果:
- 动物模型虽然有用,但往往忽略了早期人类AD病理和其他关键疾病特征.
- 动物模型和人类AD之间的神经病理和疾病进展的差异使研究结果的翻译变得复杂.
- 实验模型和研究设计的关键局限性导致AD治疗在临床试验中的高失败率.
结论:
- 对每个动物模型的神经病理学,对人类AD的忠实性和局限性的细微了解是必不可少的.
- 严格的研究设计,全面的行为评估和生物标志物利用是提高模型可靠性的必要条件.
- 解决当前临床前研究中的基本问题对于提高阿尔茨海默病治疗干预的成功率至关重要.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.3K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.8K
相关概念视频
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
